PlumX Metrics
Embed PlumX Metrics

Leucine-zipper protein, LDOC1, inhibits NF-κB activation and sensitizes pancreatic cancer cells to apoptosis

International Journal of Cancer, ISSN: 0020-7136, Vol: 105, Issue: 4, Page: 454-458
2003
  • 67
    Citations
  • 0
    Usage
  • 22
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

We have isolated a novel gene, LDOC1, which encodes for a leucine zipper protein that was downregulated in a series of human pancreatic cancer cell lines but was expressed in corresponding normal tissues. We report the initial characterization of LDOC1 as a novel regulator of the transcriptional response mediated by the nuclear factor kappa B (NF-κB). Transient expression of LDOC1 significantly inhibited the luciferase activity in LDOC1-negative BxPC-3 pancreatic cancer cell line transfected with the NF-κB reporter plasmid, activated with mitogen-activated protein kinase/ERK kinase kinase-1 (MEEK). LDOC1, however, does not affect p53, AP1 and CRE-dependent reporter gene expression. The activation of NF-κB through ligand-induced stimulation by tumor necrosis factor-α (TNF-α) or phorbol 12-myristate 13-acetate (PMA) was also inhibited by transient expression of LDOC1 in a dose dependent manner. To determine the growth effect of LDOC1 expression on cancer cells, BxPC-3 cells were stably transfected with LDOC1 cDNA. Viability studies demonstrated that TNF-α or PMA-induced antiproliferative effects were significantly enhanced by stable transfection of cells with LDOC1. These observations suggest that LDOC1 is a novel regulator of NF-κB that can affect the PMA or TNF-α-mediated pathway to apoptosis through inhibition of NF-κB activation in BxPC3 pancreatic cancer cells. © 2003 Wiley-Liss, Inc.

Bibliographic Details

Nagasaki, Koichi; Schem, Christian; von Kaisenberg, Constantin; Biallek, Marco; Rösel, Frank; Jonat, Walter; Maass, Nicolai

Wiley

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know